Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Belsomra (suvorexant by Year
Belsomra (suvorexant — insomnia orexin receptor antagonist) — International reported growth YoY (%) (%)
Merck Belsomra (suvorexant: -31.0% in FY2025.
Latest, FY2025
-31.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
5 years
Since FY2018
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Belsomra | 186 | 222 | -16 | 82 | 72 | 13 | 104 | 150 | -31”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Belsomra (suvorexant — insomnia orexin receptor antagonist) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -31.0% | – | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | -16.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | -2.0% | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 30.0% | -17.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 47.0% | – | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
Cite this data
StockData. (2026). Merck Belsomra (suvorexant (%), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-belsomra-intl-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.